RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-8.99%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$798M
AUM Growth
+$798M
(-12%)
Cap. Flow
-$2.7M
Cap. Flow
% of AUM
-0.34%
Top 10 Holdings %
Top 10 Hldgs %
29.72%
Holding
97
New
9
Increased
24
Reduced
42
Closed
4
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.9M |
| 2 |
Merck
MRK
|
$18.1M |
| 3 |
AbbVie
ABBV
|
$12.9M |
| 4 |
Esperion Therapeutics
ESPR
|
$8.94M |
| 5 |
Nektar Therapeutics
NKTR
|
$8.65M |
Top Sells
| 1 |
Horizon Bancorp
HBNC
|
$26.2M |
| 2 |
Humana
HUM
|
$11.5M |
| 3 |
Incyte
INCY
|
$8.5M |
| 4 |
HCA Healthcare
HCA
|
$7.37M |
| 5 |
Elevance Health
ELV
|
$7.2M |
Sector Composition
| 1 | Healthcare | 92.7% |
| 2 | Industrials | 0.42% |
| 3 | Technology | 0.13% |
| 4 | Financials | 0.1% |
| 5 | Energy | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$100B
| $31.5M | 3.95% | 186,000 +768 | +0.4% | +$130K |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $27.9M | 3.5% | +1,025,000 | New | +$27.9M |
|
3
NovoCure
NVCR
$1.38B
| $25.4M | 3.19% | 340,000 -25,899 | -7% | -$1.94M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $24.2M | 3.04% | 247,303 +44,286 | +22% | +$4.34M |
|
|
5
Esperion Therapeutics
ESPR
$448M
| $24M | 3.01% | 655,854 +243,761 | +59% | +$8.94M |
|
|
6
Nektar Therapeutics
NKTR
$568M
| $21.9M | 2.74% | 1,200,000 +475,000 | +66% | +$8.65M |
|
|
ABMD
7
DELISTED
Abiomed Inc
ABMD
| $21.3M | 2.68% | 120,000 +27,100 | +29% | +$4.82M |
|
8
Bristol-Myers Squibb
BMY
$96B
| $21M | 2.64% | 415,000 +76,614 | +23% | +$3.89M |
|
9
Medtronic
MDT
$119B
| $20.1M | 2.52% | 185,218 +22,335 | +14% | +$2.43M |
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $19.6M | 2.45% | 290,491 +9,142 | +3% | +$616K |
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| $19.2M | 2.41% | 150,000 -37,171 | -20% | -$4.76M |
|
12
CVS Health
CVS
$92.8B
| $19.2M | 2.4% | 303,768 -40,000 | -12% | -$2.52M |
|
13
Abbott
ABT
$231B
| $18.4M | 2.31% | 220,114 -39,438 | -15% | -$3.3M |
|
|
14
Merck
MRK
$210B
| $18.1M | 2.27% | +215,000 | New | +$18.1M |
|
15
Eli Lilly
LLY
$657B
| $16.8M | 2.1% | 150,000 -10,000 | -6% | -$1.12M |
|
16
UnitedHealth
UNH
$281B
| $16.7M | 2.1% | 77,000 -28,000 | -27% | -$6.09M |
|
17
Becton Dickinson
BDX
$55.3B
| $15.9M | 2% | 63,000 -17,000 | -21% | -$4.3M |
|
|
18
Humana
HUM
$36.5B
| $15.3M | 1.92% | 60,000 -45,000 | -43% | -$11.5M |
|
19
Boston Scientific
BSX
$156B
| $15.1M | 1.89% | 370,000 -17,908 | -5% | -$729K |
|
|
20
Elevance Health
ELV
$71.8B
| $14.4M | 1.81% | 60,000 -30,000 | -33% | -$7.2M |
|
21
Glaukos
GKOS
$5.5B
| $14.4M | 1.8% | 229,600 -6,311 | -3% | -$394K |
|
22
Neurocrine Biosciences
NBIX
$13.8B
| $13.5M | 1.69% | 149,600 -30,400 | -17% | -$2.74M |
|
|
23
AbbVie
ABBV
$372B
| $12.9M | 1.61% | +170,000 | New | +$12.9M |
|
|
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
| $12.7M | 1.59% | 148,700 +13,326 | +10% | +$1.14M |
|
25
Regeneron Pharmaceuticals
REGN
$61.5B
| $12.5M | 1.57% | 45,031 +17 | +0% | +$4.72K |
|